Royalty Report: Drugs, Drug Discovery, Cancer – Collection: 383605

$150.00

Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 10

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 10

Primary Industries

  • Drugs
  • Drug Discovery
  • Cancer
  • Therapeutic
  • Diagnostic
  • cardiac
  • Disease
  • Assay

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 383605

License Grant
This license with the Collaboration and Option Agreement, is to license exclusively one or more of the Development Candidates for development and commercialization in the Licensed Field and in the Territory.

Licensor grants the exclusive, with the right to sublicense, under the Licensor Patents and the Licensor Know-How and in the Licensed Field, to research and have researched, develop and have developed, make and have made, and use and have used the Development Candidate and to research and have researched, develop and have developed, make and have made, manufacture and have manufactured, use and have used, market and have marketed, distribute and have distributed, sell and have sold, export and import for sale, and have exported or imported for sale, Drug Products in each country in the Territory.

License Property
HDAC shall mean any histone deacetylase protein.

HDAC Inhibitor Compound shall mean any Active Compound that has a specific, desired therapeutic action through its ability to bind directly to an HDAC and inhibit HDAC activity.

IC50 shall mean the concentration of a compound that reduces activity of an enzyme by 50% in a standard, validated assay.

Field of Use
The right relates to new histone deacetylase inhibitor (“HDACi”) product candidates developed through the collaboration for treating cardiac hypertrophy and heart failure.

The Cardiac Field shall mean the research, treatment, prognosis, diagnosis, prophylaxis, and monitoring of heart muscle disease.

IPSCIO Record ID: 344537

License Grant
The Canadian Licensor grants an exclusive right and license or sublicense during the Term under the Licensed Licensor Rights to research, develop, make, have made, use, sell, distribute and import Compounds and Collaboration Products in the Field throughout the Territory pursuant to a Research and Development Program or a Commercialization Program; provided, that, Licensor retains, for itself and its Affiliates, the rights under the Licensed Licensor Rights, to research, develop, make, have made, use, sell and import Compounds and Collaboration Products in the Field throughout the Territory in order to conduct those activities assigned to it in a Research and Development Program or a Commercialization Program.  Notwithstanding the foregoing, the license shall exclude the right to make or use, other than to internally make or use for research purposes in the Field, develop, import, sell or offer for sale  Non-ND Partner Selected Compounds, and Products containing Non-ND Partner Selected Compounds, Licensor Non-ND Selected Compounds and Products containing Licensor Non-ND Selected Compounds, and Opt-Out Non-ND Partner Selected HDAC Inhibitors and Products containing Opt-Out Non-ND Partner Selected HDAC Inhibitors.

This agreement includes a non-exclusive grant back to Licensor.

License Property
Licensor has developed and owns and/or controls patents and patent applications claiming pan and isotypic selective small molecule inhibitors directly, specifically and solely targeting HDAC enzymatic activity, an enzyme family regulating gene expression, has the biological tools for research into HDAC expression in diseases, and has medicinal, combinatorial, analytical and computational expertise to design and synthesize HDAC inhibitors as well as other possible therapeutics in the Field.

Compounds means compounds that were or are identified, synthesized, discovered, designed or acquired by or on behalf of (A) Licensor or its Affiliates either prior to the date hereof or during the Term, (B) Licensee or its Affiliates during the term of the Research and Development Program, or (C) a Non-ND Partner or its Affiliates either prior to the date hereof or during the Term, but only if during the term of a Non-ND Research Program; either are HDAC Inhibitors or (b) are developed pursuant to the Collaboration (subject to the last sentence of this defined term Compound); possess certain basic drug characteristics and range of chemotypes with pan and sub-type selective HDAC inhibition characteristics, as mutually agreed to by the Parties from time to time; and are used or useful in the Field.

HDAC means HDAC Class I and HDAC Class II, collectively.

HDAC Inhibitors means Small Molecules that directly inhibit HDAC Class I or HDAC Class II enzymatic activity or which have therapeutic effect through the inhibition of HDAC Class I or HDAC Class II enzymes.

Licensor Program Compounds means the approximately(± 5%) 1014 Compounds.

Field of Use
The rights is to Licensor's HDAC inhibitors for specific neurodegenerative diseases.

Field means the treatment or prevention of Huntingtons disease, Parkinsons disease, Alzheimers disease, and the Other Neurodegenerative Diseases using an HDAC Inhibitor or any Compound developed pursuant to the Collaboration; provided, however, that the term Field shall cease to include ALS or Dementia if, as to a particular Subject Indication.

'Applicable Field' means the Field, but only as to the disease indications within the Research and Development Program that is the subject of a Back-Out (i.e., the AD R&D Program, the HD R&D Program or the PD R&D Program), in each case including any of the Other Neurodegenerative Diseases.

IPSCIO Record ID: 203362

License Grant
The parties wish to collaborate in connection with the research, development and commercialization of Licensors HDAC Inhibitors.

The Licensor of Denmark grants a co-exclusive, solely with Licensor, license in the Field throughout the Territory under the Licensors Licensed Technology, Licensors Collaboration Technology, and Licensors interest in the Joint Collaboration Technology to conduct the Research Program and to make and use Collaboration Products in connection with the Research Program, each in accordance with the terms of this Agreement.

License Property
Licensor is a biotechnology company with a development program, a library of compounds, and other intellectual property rights relating to HDAC Inhibitors.  HDAC Inhibitor shall mean a small molecule that inhibits the activity of histone deacetylase.

The patents cover Carbamic acid compounds comprising an ether linkage as HDAC inhibitors – short name HDAC-B (Ethers);  an amide linkage as HDAC inhibitors – short name HDAC-E (Amides) ;  a sulfonamide linkage as HDAC inhibitors – short name HDAC-F (Sulfonamides);  an ester or ketone linkage as HDAC inhibitors – short name HDAC-H (Ketones/Esters);  a piperazine linkage as HDAC inhibitors – short name HDAC-1 (Piperazines); and a bicyclic heteroaryl group as HDAC inhibitors – short name HDAC-J (Quinoxalines).

PXD101 is a novel histone deacetylase (HDAC) inhibitor for the treatment of solid and hematological cancers. PXD101 is currently in a Phase I clinical trial in patients with advanced solid tumors and is one of the most advanced HDAC inhibitors in development. HDAC inhibitors are a new class of potential anti-cancer agents that have shown promise in preclinical and clinical studies.

Patent family 'Carbamic acid compounds comprising an amide linkage as HDAC inhibitors' – short name ' HDAC-E (Amides)'
USA 10/381794
USA 10/381791

Patent family 'Carbamic acid compounds comprising a sulfonamide linkage as HDAC inhibitors – short name 'HDAC-F (Sulfonamides) '
USA 60/297784
USA 60/308136
USA 10/381790

Field of Use
The Field shall mean the prevention, diagnosis, control or treatment of any human disease or condition by use of a Collaboration Product, either as a single agent or in combination with any other therapy.

IPSCIO Record ID: 344538

License Grant
By this agreement, The Canadian Licensor shall Back-Out of all further research, development and commercialization of all Compounds and resulting Collaboration Products.  Licensee shall proceed unilaterally with the research development and commercialization of all such Compounds and Collaboration products in the Field, and shall become the Pursuing Party with respect thereto.

The collaboration shall continue as stated in the original agreement, with this Pursuing Party change.  The original agreement has conditional exclusivity.

License Property
Per the original agreement, Collaboration Products means all products which contain a Compound or a Licensee HDAC Inhibitor as an active ingredient.
Field of Use
HDAC inhibitors are for specific neurodegenerative diseases.

The field as identified in the original agreement means the treatment or prevention of Huntingtons disease, Parkinsons disease, Alzheimers disease, and the Other Neurodegenerative Diseases using an HDAC Inhibitor or any Compound developed pursuant to the Collaboration; provided, however, that the term Field shall cease to include ALS or Dementia if, as to a particular Subject Indication.

IPSCIO Record ID: 203375

License Grant
The Licensors grant an exclusive license under Licensed Subject Matter to discover, research, develop, make, have made, use, offer for sale, sell and import licensed products and identified products within Licensed Territory for use within Licensed Field to
– Publish the general scientific findings from research related to Licensed Subject Matter and Licensed Products subject to the confidentiality terms, and
– Use Licensed Subject Matter or Identified Products solely for research, teaching and other educationally-related, non-commercial purposes only.
License Property
The patents are for Transgenic Animal Models for Cardiac hypertrophy and Methods and Use Thereof, Transgenic Animal Models for Cardiac hypertrophy and Methods and Use Thereof,  Transgenic Animal Models for Cardiac hypertrophy and Methods and Use Thereof and Methods and Compositions for Therapeutic Intervention in Cardiac Hypertrophy.

Licensed Product means any compound, assay, method, reagent, technology, or product comprising Licensed Subject Matter pursuant to this Agreement.

Licensed Subject Matter means inventions and discoveries claimed in Patent Rights or covered by Technology Rights within Licensed Field.

Technology Rights means Licensors rights in technical information, know-how, processes, procedures, compositions, devices, methods, formulas, protocols, techniques, software, designs, drawings or data created by Inventors relating to Licensed Subject Matter which are not covered by Patent Rights, but useful.

Field of Use
Licensed Field means the discovery, development, manufacture, use, sale, offer for sale, and import of pharmaceutical, biologic, gene therapy and/or health care products for the treatment, prevention and/or diagnosis of cardiac hypertrophy and heart failure by inhibition of calcineurin activity and calmodulin-dependent protein activity, and NFAT activity; the development, manufacture and use of assays for the identification of pharmaceutical and/or biologic agents for the treatment, prevention, and/or diagnosis of cardiac hypertrophy and heart failure by inhibition of calcineurin activity and calmodulin-dependent protein activity, and NFAT activity; and the development, manufacture and use of assays useful in the diagnosis of, prognosis of, or determination of predisposition to, cardiac hypertrophy and heart failure by inhibition of calcineurin activity and calmodulin-dependent protein activity, and NFAT activity.

IPSCIO Record ID: 223149

License Grant
The parties agree to amend certain terms relating to the payment due upon execution of this agreement and terms of the royalties payments.  The parties had entered into an assignment agreement whereby the Licensor had assigned to Licensee certain proprietary technology and know-how related to the Licensor Programs, including but not limited to the HDAC Program (the Original Assignment Agreement).
License Property
HDAC Program – histone deacetylase inhibitor relating to small molecule drug candidates for the treatment of cancer and other diseases.
Field of Use
This agreement pertains to the drug industry.

IPSCIO Record ID: 240578

License Grant
The University grants a worldwide, exclusive license under Licensed Subject matter to discover, research, develop, make, have made, use offer for sale, sell and import Licensed Products and Identified Products for use within Licensed Field.
License Property
Licensed Product means any compound, assay, method, reagent, technology, product or service comprising Licensed Subject Matter.

Licensed Subject Matter means inventions, discoveries, assays and processes covered by Patent Rights and/or Technology Rights within Licensed Field.

The patents are for Methods and Compositions Relating to Muscle Selective Calcineurin Interacting Protein (MCIP).

Field of Use
Licensed field means treatment, prevention, diagnosis and/or prognosis of cardiac hypertrophy, heart disease and heart failure; and determination of predisposition to cardiac hypertrophy, heart disease and heart failure.

IPSCIO Record ID: 245875

License Grant
Licensor grants to the German Licensee an exclusive, non-transferable license in the Field under the Licensor Patents, Licensor Know-How and Licensors rights in the Joint Patents, Joint Inventions and Joint Know-How to make, have made, use, register, sell, offer to sell, import, export, exploit, Research, Develop and Commercialize Licensee BACE Compounds, BACE Collaboration Compounds, Potential Development Candidates, Development Candidates and Products in the Territory.
License Property
The patents are for Inhibitors of Beta Secretase

BACE Collaboration Compound means a compound that is a BACE Inhibitor, and is discovered by either or both Parties or their Affiliates during the Research Term, or is acquired by either or both Parties or their Affiliates during the Research Term, or was discovered by Licensor prior to the Research Term. BACE Collaboration Compounds discovered prior to the Effective Date by Licensor.

BACE Inhibitor means a compound that at Licensor inhibits human BACE enzyme activity by fifty percent (50%) at a concentration (IC50) of less than one micromole per liter ( <l µmol/L) in an in vitro assay in which the Licensor inhibitor standard, I-!4848, has an ICso of less than fifteen nanomoles per liter (<15 nmoVL) in an assay following the protocol as currently performed at Vitae and/or a compound that at Licensee inhibits human BACE enzyme activity by fifty percent (50%) at an ICso of less than one micromole per liter (<l µmol/L) in in vitro assays in which the Licensee standard inhibitor, N-((1S,2R)-1-benzyl-3- cyclopropylamino-2-hydroxy-propyl)-5-(methanesulfonyl-methyl-amino )-N-( (R)-1-phenylethyl)-isophthalamide (compound 3 from Stachel et al. J. Med. Chem. 2004, 47, 6447-6450) has an IC50 of less than or equal to seventy nanomoles per liter (s70 nmol/L) in assays following the protocols as currently performed at Licensee.

Field of Use
The Field means the diagnosis, treatment, palliation or prevention of all human and animal diseases including, but not limited to, Core Indications.

Licensee is responsible for the development and commercialization of BACE inhibitors for the treatment of Alzheimer's disease and other forms of dementia.

IPSCIO Record ID: 299249

License Grant
For the Research Licenses, Licensor grants, during the Research Term an exclusive, world-wide right and license under the Licensor Patents and the Licensor Know-How and Licensors rights in the Joint Patents and Joint Know-How, solely to conduct the Research, and to discover, synthesize, and, in connection with the Research, make and use Active Compounds for use in the Field.

Licensor grants, commencing at the expiration of the Research Term and for a period of six years thereafter, a non-exclusive, world-wide right and license under the Licensor Patents and Licensor Know-How, and Licensors rights in the Joint Patents and Joint Know-How, solely to discover, synthesize, and, in connection with Licensees activities under this Agreement, make and use Active Compounds for use in the Field.

For the Commercialization License to Licensee, Licensor grants an exclusive, world-wide right and license under the Licensor Patents, the Licensor Know-How and under Licensors rights in the Joint Know-How and Joint Patents, solely to [conduct development on, and to make, have made and use for such purpose, Back-Up Compounds and Collaboration Compounds for use in the Field and to make, have made, import, use, sell and offer for sale Licensed. Products) for use in the Field.

For the Cross-License of Know-How Licensor grants a non-exclusive license under the Licensor Know-How for any purpose or use.

License Property
Licensor has proprietary technology and know-how related to the discovery, identification and/or synthesis of cathepsin S inhibitors and have identified chemical compounds that are cathepsin S inhibitors.

Licensed Product means any product, including any formulation thereof, containing or comprising a Collaboration Compound.

Active Compound means any compound that
—  has the ability to inhibit (or, in the case of a prodrug, an active species of which inhibits) cathepsin S with a [K; equal to or less than 100 nM];
—  has greater than [100- fold selectivity] for cathepsin S against an [appropriate panel of cathepsins in appropriate assays,] as determined by the JRC; and
—  has appropriate [in-cell activity in concentrations of less than IO µMin a relevant cell based assay(s)] selected by the JRC.

Field of Use
Field means the treatment and/or prevention of one or more Indications by means of inhibition of cathepsin S.

Cathepsin S is associated with certain inflammatory diseases, such as arthritis, asthma, atherosclerosis and a variety of autoimmune diseases.

Cysteine proteases are enzymes that are responsible for the cleavage and breakdown of other natural proteins in normal biological processes. In disease conditions, cystein proteases can often be misregulated, providing an entry point for drug intervention. Cathepsin S has been associated with the processing and activation of the antigen receptor called MHC-II, essential for the initiation of both normal and pathological immune responses mediated by T-cells. Drugs designed to inhibit this enzyme may provide a novel method for control of antigen-induced response in multiple inflammatory and autoimmune disease states, the companies believe.

IPSCIO Record ID: 289175

License Grant
For the Commercial License to Clinical Candidates and Corresponding Products, Licensor grant an exclusive license, with the right to grant and authorize sublicenses through multiple tiers, under the Licensor Technology and Licensors interest in the applicable Collaboration Technology, to make, have made, use, offer for sale, sell, import, export and otherwise exploit Active Compounds, Clinical Candidates, Lead Compounds and Products for use in the Field and in the Territory.
License Property
The Parties have each identified multiple oncology kinase targets that have the potential to be used as the basis for drug discovery programs.

Active Compound shall mean a Compound that modulates a Target, the mechanism of which is a binding interaction with a Target, having a level of activity against a Target, expressed as an IC50, that is – less than forty (40) nanomolar- as measured in the applicable in vitro biochemical assay set forth in the Discovery Plan; and a Compound that modulates at least two of the following receptors TrkA, TrkB or TrkC, the mechanism of which is a binding interaction with the applicable Trk receptor, having a level of activity against the applicable Trk receptor, expressed as an ICso, that is less than forty (40) nanomolar as measured in the applicable in vitro biochemical assay set forth in the Discovery Plan.

Clinical Candidate shall mean, with respect to each Target or Trk, any Active Compound that meets the Clinical Candidate Criteria set forth in the Discovery Plan.

Compound shall mean any one or more chemical entity(ies) made and tested against Trk in the course of Licensors pan-Trk program prior to the Effective Date, or synthesized by Licensor in the course of performing or in connection with the Discovery Program, in each case together with any salt, hydrate, solvate, clathrate, polymorph or isomer thereof.

Product shall mean any pharmaceutical product incorporating as an active ingredient an Active Compound.

Trk shall mean the Trk family of receptors TrkA, Tr kB and TrkC.
—  TrkA shall mean the protein known as UniProtKB/Swiss-Prot # P04629.
—  TrkB shall mean the protein known as UniProtKB/Swiss-Prot # Q16620.
—  TrkC shall mean the protein known as UniProtKB/Swiss-Prot # Q16288.

The Targets are
—  The protein family commonly known as Firbroblast Growth Factor Receptors (FGFR),
—  The protein commonly known as [p70S6 Kinase], identified with the following SwissProt entries
a) Ribosomal protein S6 kinase beta-1 (P23443)
b) Ribosomal rotein S6 kinase beta-2 (Q9UBS0]—  The protein commonly known as Telomerase reverse transcriptase, identified with the following SwissProt entries
a) Telomerase reverse transcriptase (014746)
b) Telomerase protein component 1 (Q99973)

Field of Use
The development and commercialization agreement pertain to certain Array-invented compounds targeted at a specified novel oncogenic activating mutation.

Licensee possesses pharmaceutical research, development and commercialization capabilities, as well as proprietary technology in the field of cancer treatment.

Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.